Darell D Bigner Selected Research

transforming growth factor(alpha)-Pseudomonas aeruginosa exotoxin (38)

1/2005	Sustained radiographic and clinical response in patient with bifrontal recurrent glioblastoma multiforme with intracerebral infusion of the recombinant targeted toxin TP-38: case study.
10/2003	Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Darell D Bigner Research Topics

Disease

145	Neoplasms (Cancer) 01/2023 - 01/2002
101	Glioma (Gliomas) 09/2023 - 01/2002
75	Glioblastoma (Glioblastoma Multiforme) 09/2023 - 01/2004
46	Brain Neoplasms (Brain Tumor) 01/2023 - 11/2002
14	Medulloblastoma 01/2023 - 07/2002
11	Melanoma (Melanoma, Malignant) 01/2021 - 01/2002
7	Inflammation (Inflammations) 01/2023 - 11/2016
7	Lymphopenia (Lymphocytopenia) 06/2013 - 02/2008
6	Poliomyelitis (Polio) 01/2023 - 11/2014
6	Bites and Stings (Sting) 01/2022 - 07/2011
5	Hypersensitivity (Allergy) 09/2023 - 04/2009
5	Infections 01/2023 - 02/2009
5	Astrocytoma (Pilocytic Astrocytoma) 01/2019 - 01/2006
5	Breast Neoplasms (Breast Cancer) 01/2019 - 02/2002
5	Carcinogenesis 01/2017 - 01/2011
4	Oligodendroglioma 12/2009 - 01/2006
3	Neoplasm Metastasis (Metastasis) 01/2019 - 01/2016
3	Lung Neoplasms (Lung Cancer) 01/2018 - 08/2004
3	Hypoxia (Hypoxemia) 01/2016 - 08/2006
2	Disease Progression 01/2021 - 10/2005
2	Prostatic Neoplasms (Prostate Cancer) 01/2018 - 11/2016
2	Head and Neck Neoplasms (Head and Neck Cancer) 09/2014 - 09/2006

Drug/Important Bio-Agent (IBA)

44	ErbB Receptors (EGF Receptor)IBA 01/2023 - 01/2002
41	epidermal growth factor receptor VIIIIBA 01/2023 - 01/2002
31	Proteins (Proteins, Gene)FDA Link 01/2023 - 05/2003
29	Monoclonal AntibodiesIBA 01/2016 - 01/2002
22	Temozolomide (Temodar)FDA LinkGeneric 01/2016 - 09/2002
21	AntigensIBA 01/2023 - 01/2002
17	VaccinesIBA 01/2023 - 02/2002
16	Immunotoxins (Immunotoxin)IBA 01/2019 - 01/2005
11	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 01/2019 - 02/2009
9	DNA (Deoxyribonucleic Acid)IBA 01/2019 - 09/2002
8	Peptides (Polypeptides)IBA 03/2013 - 01/2002
7	Bevacizumab (Avastin)FDA Link 01/2023 - 08/2006
7	EnzymesIBA 01/2019 - 02/2006
7	Phosphotransferases (Kinase)IBA 12/2015 - 12/2004
7	Irinotecan (Camptosar)FDA LinkGeneric 06/2011 - 09/2002
7	O(6)-benzylguanineIBA 10/2009 - 05/2002
7	Carmustine (FIVB)FDA Link 08/2009 - 05/2002
6	MethyltransferasesIBA 01/2022 - 10/2005
6	Biomarkers (Surrogate Marker)IBA 01/2022 - 03/2009
6	Neoplasm Antigens (Tumor Antigens)IBA 01/2020 - 05/2009
6	CytokinesIBA 01/2016 - 06/2004
5	poliovirus receptorIBA 01/2023 - 07/2004
5	RNA (Ribonucleic Acid)IBA 01/2022 - 03/2015
5	Telomerase (Telomerase Reverse Transcriptase)IBA 01/2019 - 04/2013
5	Single-Chain AntibodiesIBA 01/2018 - 01/2006
5	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 09/2017 - 08/2006
5	D2C7-(scdsFv)-PE38KDELIBA 04/2017 - 09/2013
5	NADP (NADPH)IBA 01/2013 - 02/2009
5	N-succinimidyl 4-guanidinomethyl-3-iodobenzoateIBA 10/2010 - 01/2002
5	Alkyl and Aryl TransferasesIBA 02/2009 - 09/2002
5	Tyrosine Kinase InhibitorsIBA 11/2005 - 11/2002
4	MicroRNAs (MicroRNA)IBA 01/2016 - 01/2011
4	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2013 - 11/2002
4	isocitric acid (isocitrate)IBA 12/2012 - 02/2009
4	Oxidoreductases (Dehydrogenase)IBA 12/2012 - 02/2009
4	Cytotoxins (Cytolysins)IBA 01/2012 - 02/2007
4	Glycoproteins (Glycoprotein)IBA 07/2011 - 04/2006
4	TenascinIBA 05/2007 - 08/2004
4	Gefitinib (Iressa)FDA Link 02/2006 - 11/2002
3	Histones (Histone)IBA 01/2023 - 01/2011
3	LigandsIBA 01/2023 - 06/2004
3	ProteomeIBA 01/2018 - 10/2009
3	Messenger RNA (mRNA)IBA 01/2018 - 04/2006
3	ExotoxinsIBA 04/2017 - 10/2003
3	alpha-hydroxyglutarateIBA 01/2017 - 02/2011
3	Chimeric Antigen ReceptorsIBA 03/2016 - 01/2014
3	Tyrosine (L-Tyrosine)FDA Link 12/2015 - 06/2007
3	Antineoplastic Agents (Antineoplastics)IBA 12/2013 - 11/2012
3	GangliosidesIBA 09/2013 - 01/2010
3	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 03/2013 - 02/2006
3	Amino Acids FDA Link 01/2013 - 04/2006
3	Protein Subunit VaccinesIBA 01/2013 - 02/2008
3	1,3,4,6-tetrachloro-3 alpha,6 alpha-diphenylglycolurilIBA 01/2012 - 05/2003
3	Human Serum Albumin FDA LinkGeneric 09/2011 - 02/2007
3	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 01/2011 - 01/2005
3	Heat-Shock Proteins (Heat-Shock Protein)IBA 10/2009 - 05/2006
3	Transforming Growth Factor beta (TGF-beta)IBA 05/2009 - 06/2004
2	Pattern Recognition ReceptorsIBA 01/2023 - 01/2021
2	Neutralizing AntibodiesIBA 01/2023 - 08/2006
2	ChromatinIBA 01/2023 - 07/2012
2	Immune Checkpoint InhibitorsIBA 01/2021 - 01/2019
2	A-factor (Streptomyces)IBA 01/2019 - 01/2011
2	chondroitin sulfate proteoglycan 4IBA 01/2019 - 01/2017
2	Therapeutic UsesIBA 01/2018 - 08/2009
2	Formaldehyde (Formol)FDA Link 12/2017 - 01/2016
2	ParaffinIBA 12/2017 - 01/2016
2	AntibodiesIBA 01/2017 - 08/2010
2	ChemokinesIBA 11/2016 - 03/2015
2	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2016 - 01/2006
2	Conditioned Culture MediaIBA 01/2016 - 08/2006
2	rindopepimutIBA 06/2015 - 03/2013

Therapy/Procedure

81	Therapeutics 01/2023 - 08/2003
34	Immunotherapy 01/2023 - 02/2002
22	Drug Therapy (Chemotherapy) 01/2019 - 01/2004
10	Radiotherapy 07/2013 - 06/2005
4	Catheters 01/2023 - 02/2007
4	Radioimmunotherapy 05/2007 - 09/2005
2	Chemoradiotherapy 01/2016 - 01/2011